Articles published by Nimbus Therapeutics, LLC

Nimbus Therapeutics Announces Completion of Dose Escalation in Phase 1/2 Clinical Trial of NDI-219216, Novel WRN Inhibitor for MSI-H Tumors

Today 8:00 EST

From Nimbus Therapeutics, LLC

Via Business Wire

Nimbus Therapeutics Announces Initiation of First-in-Human Clinical Trial with NDI-219216, Novel WRN Inhibitor for MSI-H Tumors

April 25, 2025

From Nimbus Therapeutics, LLC

Via Business Wire

Nimbus Therapeutics Appoints Abbas Kazimi as Chief Executive Officer

March 07, 2025

From Nimbus Therapeutics, LLC

Via Business Wire

Nimbus Therapeutics Achieves Research Milestone in Collaboration with Lilly

February 25, 2025

From Nimbus Therapeutics, LLC

Via Business Wire

Nimbus Therapeutics Presents Positive Updated Data from Phase 1/2 Clinical Trial of HPK1 Inhibitor for Advanced Solid Tumors at SITC 39th Annual Meeting

November 07, 2024

From Nimbus Therapeutics, LLC

Via Business Wire

Nimbus Therapeutics Presents First Preclinical Data on Novel WRN Inhibitor NTX-452 at 36th EORTC-NCI-AACR Symposium

October 23, 2024

From Nimbus Therapeutics, LLC

Via Business Wire

Nimbus Therapeutics to Present First Preclinical Data from Werner Syndrome Helicase Program at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

October 09, 2024

From Nimbus Therapeutics, LLC

Via Business Wire

Nimbus Therapeutics Presents New Positive Monotherapy Phase 1/2 Clinical Data of HPK1 Inhibitor in Treatment of Advanced Solid Tumors at 2024 ASCO Annual Meeting

May 23, 2024

From Nimbus Therapeutics, LLC

Via Business Wire

Nimbus Therapeutics Appoints Anita Scheuber, M.D., Ph.D., as Senior Vice President, Therapeutic Area Head, Oncology

May 07, 2024

From Nimbus Therapeutics, LLC

Via Business Wire

Nimbus Therapeutics Appoints Katharine Knobil, M.D., to Board of Directors

March 12, 2024

From Nimbus Therapeutics, LLC

Via Business Wire

Nimbus Therapeutics Announces Expansion of Its Immunology Drug Discovery Pipeline

January 05, 2024

From Nimbus Therapeutics, LLC

Via Business Wire

Nimbus Therapeutics Presents Positive Preliminary Data from Clinical Trial of HPK1 Inhibitor in Solid Tumors at SITC Annual Meeting

October 31, 2023

From Nimbus Therapeutics, LLC

Via Business Wire

Nimbus Therapeutics Secures $210M Private Financing to Advance Next Wave of Tech-Enabled Small Molecule Medicines

September 06, 2023

From Nimbus Therapeutics, LLC

Via Business Wire

Nimbus Therapeutics Announces Closing of Takeda’s Acquisition of TYK2 Subsidiary

February 08, 2023

From Nimbus Therapeutics, LLC

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.